‘Because we have such a low cash cost operation, our margin is still very healthy and in fact we are in the lowest 10% of cash cost producers internationally. So whilst we’d like to make more money, we still make quite a bit at current copper prices,’ he says. Clarke explains what the company looks for in a project and his plans for Central Asia’s burgeoning cash pile.
Meet Alliance Pharma plc, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event, London , 24 January 2019. Register here »